Insider · CIK 0001669866
Marino Garcia
Files at DNTH (Dianthus Therapeutics, Inc. /DE/), AGMB (AgomAb Therapeutics NV). First filing Mar 13, 2026, latest Aug 7, 2026.
In brief
Marino Garcia files SEC Form 4 as CEO, president and director at DNTH (Dianthus Therapeutics, Inc. /DE/), and also at AGMB (AgomAb Therapeutics NV). Since Mar 13, 2026, Marino Garcia has reported 0 open-market buys worth $0 and 2 open-market sells worth $28M, the latest filed on Aug 7, 2026.
A track record needs three past buys with six months of prices behind them; Marino Garcia has 0, so none is measured yet.
The newest scored trade: sold $18M of DNTH on Aug 7, 2026, filed Aug 7, 2026, scored 50 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $28M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNTH: Dianthus Therapeutics, Inc. /DE/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Dianthus Therapeutics, Inc. /DE/ | $18M 166,000 shares | -72% | +481% from low-3% from high | |
| 50Moderate | Dianthus Therapeutics, Inc. /DE/ | $10M 122,918 shares | -100% | +441% from low-8% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 7, 2026 | DNTH DIANTHUS THERAPEUTICS OPCO, INC. | 126,000 0.23% of outstanding | $14M | Aug 7, 2026 | none |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. | 40,000 0.07% of outstanding | $4.4M | Aug 7, 2026 | none |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. | 122,918 0.28% of outstanding | $11M | Mar 12, 2026 | none |
Transactions
Every row this insider has filed, 26 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | AGMB AgomAb Therapeutics NV | AGrant or award Stock Option (Right to Buy)derivative | +57,482 | $0.00 | $0 | 57,482 | 28 d ago |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +40,000 | $8.44 | $338k | 105,292 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +126,000 | $8.44 | $1.1M | 231,292 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -10,384 | $107.49 | $1.1M | 220,908 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -23,907 | $108.05 | $2.6M | 197,001 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -2,373 | $109.10 | $259k | 194,628 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -2,536 | $110.02 | $279k | 192,092 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -800 | $110.76 | $89k | 191,292 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -104,091 | $107.96 | $11M | 87,102 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -21,909 | $108.72 | $2.4M | 65,292 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 286,004 | Aug 7, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -126,000 | $0.00 | $0 | 160,004 | Aug 7, 2026 |
| Mar 16, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock | +59,700 | $6.70 | $400k | 59,700 | Mar 17, 2026 |
| Mar 16, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock | +5,592 | $17.88 | $100k | 65,292 | Mar 17, 2026 |
| Mar 16, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative | -59,700 | $0.00 | $0 | 41 | Mar 17, 2026 |
| Mar 16, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative | -5,592 | $0.00 | $0 | 269,408 | Mar 17, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +122,918 | $6.70 | $824k | 122,918 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -43,505 | $80.69 | $3.5M | 79,413 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -65,517 | $81.74 | $5.4M | 13,896 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -12,796 | $82.60 | $1.1M | 1,100 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -200 | $83.38 | $17k | 900 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -900 | $85.53 | $77k | 0 | Mar 13, 2026 |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -122,918 | $0.00 | $0 | 59,741 | Mar 13, 2026 |
| Feb 3, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +355,000 | $0.00 | $0 | 355,000 | Feb 4, 2026 |
| Sep 30, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Oct 3, 2025 |
| Feb 3, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +340,000 | $0.00 | $0 | 340,000 | Feb 4, 2025 |
Questions about Marino Garcia
Answered from the filings on this page, as of the latest one.
Is Marino Garcia buying or selling?
In the last 12 months Marino Garcia reported 0 open-market buys worth $0 and 2 open-market sells worth $28M on SEC Form 4; the latest was sold $18M of DNTH on Aug 7, 2026. Grants, option exercises and tax withholding are not counted.
How did Marino Garcia's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Marino Garcia has 0.
Where does Marino Garcia file Form 4?
Marino Garcia has filed Form 4 at DNTH (Dianthus Therapeutics, Inc. /DE/) as CEO AND PRESIDENT; AGMB (AgomAb Therapeutics NV). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.